AbbVie, Inc. v. Deva Holding A.S.
Infringement action filed 30 Oct 2025 in the United States District Court for the District of Delaware and closed 15 Jun 2026, with 5 patents asserted. Recorded basis of termination: dismissed without prejudice.
Case record
- Patents involved
- US7943621B2USRE47350E1US7737142B2USRE49302E1USRE49110E1
- Case no.
- 1:25-cv-01332
- Verdict cause
- Infringement action
- Court
- D. Del.
- Court level
- District Court
- Case region
- Delaware
- Chief judge
- Maryellen Noreika
- Trial level
- First instance
- Filed – Closed
- 30 Oct 2025 – 15 Jun 2026
- Duration
- 228 days
- Basis of termination
- Dismissed without Prejudice
- Products & marks
- VRAYLAR® (cariprazine capsules, 1.5 mg, 3 mg, 4.5 mg, and 6 mg)
Check this patent against your own product
Prior art, claim scope, infringement exposure and design-around routes. Every answer cites the records behind it.
Get an FTO claim chart- 01Ranked prior artEvery hit source-linked
- 02Claim-level comparisonAgainst your own product
- 03Legal statusAcross 174 jurisdictions
Salts of piperazine compounds as D3/D2 antagonists
The present invention relates to novel monohydrochloride, dihydrochloride, monohydrobromide, maleate and methanesulphonate salts of trans 4-{2-[4-(2,3-dichlorophenyl)-piperazine-1-yl]-ethyl}-N,N-dimethylcarbamoyl-cyclohexylamine and/or their hydrates and/or solvates. Moreover, the invention relates to the process for preparing the salts and their hydrates and/or solvates, to their use in the treatment and/or prevention of conditions which require modulation of dopamine receptor and to pharmaceutical compositions containing them.
- Legal status
- Active
- Granted
- 17 May 2011
- Est. expiry
- 20 Jun 2029
- Validity challenges
- None recorded
- Licences recorded
- None recorded
- Inventors
- CZIBULA, LASZLO · SEBOK, FERENC · GREINER, ISTVAN · DOMANY, GYORGY · CSONGOR, EVA AGAINE
- Classification
- A61K31/497C07D295/00
- Prosecution counsel
- FISH & RICHARDSON P.C.
- Examiner
- WILSON, JAMES O
Pharmaceutical formulations containing dopamine receptor ligands
The present invention relates to stable and bioavailable immediate release formulations comprising dopamine receptor ligands. Methods of treating various disorders by administering the formulations are also described.
- Legal status
- Active
- Granted
- 16 Apr 2019
- Earliest priority
- 16 Jul 2008
- Est. expiry
- 16 Jan 2030
- Validity challenges
- None recorded
- Licences recorded
- None recorded
- Inventors
- SARKAR, RANAJOY · DEDHIYA, MAHENDRA G. · CHHETTRY, ANIL
- Classification
- A61K31/495C07D295/135A61K9/20A61K9/48
- Prosecution counsel
- FISH & RICHARDSON P.C.
- Examiner
- RAILEY, II, JOHNNY F
Also asserted in this case
3 moreThe docket lists 5 asserted patents. Full bibliographic detail, drawings and prosecution history for the remaining 3 asserted patents are one query away in Eureka.
Parties of record
AbbVie, Inc.
- Core tech
- Not recorded
- Counsel
- Alexander Trzeciak · Christine Smith · Christopher N. Sipes · Jeremy A. Tigan · Megan Elizabeth Dellinger · Michael R. Morey
- Firm
- Morris, Nichols, Arsht & Tunnell LLP
Deva Holding A.S.
- Core tech
- Not recorded
- Counsel
- Dominick T. Gattuso · Shashank S. Upadhye · Yixin H. Tang
- Firm
- Heyman Enerio Gattuso & Hirzel, LLP
Counsel of record
| Attorney | For | Role |
|---|---|---|
| Alexander Trzeciak | AbbVie, Inc. | Plaintiff |
| Christine Smith | AbbVie, Inc. | Plaintiff |
| Christopher N. Sipes | AbbVie, Inc. | Plaintiff |
| Jeremy A. Tigan | AbbVie, Inc. | Plaintiff |
| Megan Elizabeth Dellinger | AbbVie, Inc. | Plaintiff |
| Michael R. Morey | AbbVie, Inc. | Plaintiff |
| Dominick T. Gattuso | Deva Holding A.S. | Defendant |
| Shashank S. Upadhye | Deva Holding A.S. | Defendant |
| Yixin H. Tang | Deva Holding A.S. | Defendant |
Basis of termination
From the record · verbatim“Accordingly, pursuant to the above Stipulation, and upon the consent and request of Plaintiffs and Deva, IT IS HEREBY ORDERED, ADJUDGED, AND DECREED THAT: Case 1:25-cv-01332-MN Document 36 Filed 06/15/26 Page 2 of 4 PageID #: 289 3 1. The filing of ANDA 219532 was a technical act of infringement of each of the ’142 Patent, the ’621 Patent, the RE’350 Patent, the RE’110 Patent, and the RE’302 Patent under 35 U.S.C. § 271(e)(2)(A). 2. All other claims and defenses asserted by the parties against each other in Plaintiffs’ and Deva’s pleadings in the Action, including the allegations and averments contained therein, are hereby dismissed, without prejudice. 3. Deva, its officers, agents, servants, employees, and attorneys, and all other persons in active concert or participation with any of them who receive actual notice of this Order by personal service or otherwise, are hereby enjoined from manufacturing, using, offering to sell, or selling within the United States, or importing into the United States, the generic cariprazine hydrochloride capsule products (1.5 mg, 3 mg, 4.5 mg, and 6 mg) described by ANDA 219532 during the life of the ’142 Patent, the ’621 Patent, the RE’350 Patent, the RE’110 Patent, and the RE’302 Patent, including any extensions and pediatric exclusivities thereof, absent a license agreement or other authorization by Plaintiffs, unless all of the claims of the ’142 Patent, the ’621 Patent, the RE’350 Patent, the RE’110 Patent, and the RE’302 Patent are found invalid or unenforceable by a court decision from which no appeal has been or can be taken, other than a petition for a writ of certiorari to the U.S. Supreme Court. 4. Plaintiffs and Deva each expressly waive any right to appeal or otherwise move for relief from this Stipulation and Order. 5. This Court retains jurisdiction over Plaintiffs and Deva for purposes of enforcing this Stipulation and Order. 6. This Stipulation and Order shall finally resolve the Action.This Stipulation and Order is without prejudice to any claim, defense, or counterclaim in any possible future action between Deva and any of the Plaintiffs regarding the ’142 Patent, the ’621 Patent, the RE’350 Patent, the RE’110 Patent, and the RE’302 Patent and a product other than a generic cariprazine hydrochloride capsule product (1.5 mg, 3 mg, 4.5 mg, and 6 mg) described by ANDA 219532. “”
Case 1:25-cv-01332 · D. Del. · closed 15 June 2026
Related cases
Three questions this record usually leads to. Each one runs against the full litigation and patent corpus, and cites what it finds.
Frequently asked questions
What is case 1:25-cv-01332?
1:25-cv-01332 is a patent infringement action brought by AbbVie, Inc. against Deva Holding A.S., filed on 30 Oct 2025 in the United States District Court for the District of Delaware. The case closed on 15 June 2026.
Which patents were asserted in 1:25-cv-01332?
US7943621B2 (“Salts of piperazine compounds as D3/D2 antagonists”), assigned to RICHTER GEDEON NYRT., currently active; USRE47350E1 (“Pharmaceutical formulations containing dopamine receptor ligands”), assigned to RICHTER GEDEON NYRT., currently active; US7737142B2 (“(Thio)carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists”), assigned to RICHTER GEDEON NYRT.; USRE49302E1 (“Pharmaceutical formulations containing dopamine receptor ligands”), assigned to RICHTER GEDEON NYRT.; USRE49110E1 (“Pharmaceutical formulations containing dopamine receptor ligands”), assigned to RICHTER GEDEON NYRT.. The record also lists VRAYLAR® (cariprazine capsules, 1.5 mg, 3 mg, 4.5 mg, and 6 mg).
How was case 1:25-cv-01332 terminated?
The recorded basis of termination is dismissed without prejudice. The termination text reads: “Accordingly, pursuant to the above Stipulation, and upon the consent and request of Plaintiffs and Deva, IT IS HEREBY ORDERED, ADJUDGED, AND DECREED THAT: Case 1:25-cv-01332-MN Document 36 Filed 06/15/26 Page 2 of 4 PageID #: 289 3 1. The filing of ANDA 219532 was a technical act of infringement of each of the ’142 Patent, the ’621 Patent, the RE’350 Patent, the RE’110 Patent, and the RE’302 Patent under 35 U.S.C. § 271(e)(2)(A). 2. All other claims and defenses asserted by the parties against each other in Plaintiffs’ and Deva’s pleadings in the Action, including the allegations and averment
What does dismissal without prejudice mean?
A dismissal without prejudice ends this action but leaves the claims alive — the plaintiff may file them again later, subject to the limitation period.
How long did case 1:25-cv-01332 take?
228 calendar days, from filing on 30 Oct 2025 to closure on 15 June 2026.
Who were the attorneys and the judge in 1:25-cv-01332?
Chief Judge Maryellen Noreika presided. Alexander Trzeciak, Christine Smith, Christopher N. Sipes, Jeremy A. Tigan, Megan Elizabeth Dellinger and Michael R. Morey are recorded as counsel for plaintiff AbbVie. Dominick T. Gattuso, Shashank S. Upadhye and Yixin H. Tang appear for defendant Deva Holding A.S..
Disclaimer. This page reproduces publicly available court docket data for case 1:25-cv-01332 and is provided for general information and reference only. It is not legal advice and must not be relied upon as such.
Docket data has limits. Records are drawn from a snapshot and may lag the live docket. Sealed filings, amended complaints, counterclaims and post-closure motions may not be reflected. Party names, attorney names and firm affiliations are reproduced as recorded and may contain omissions. Where a field is absent from the record, this page marks it as not recorded rather than inferring a value.
No characterisation of the parties or the outcome. This page reports what the record contains. Nothing here should be read as an assertion that any party infringed, that any patent is valid or invalid, that any settlement occurred, or that any party prevailed.
No FTO or validity opinion. Nothing on this page constitutes a freedom-to-operate, novelty, validity or infringement opinion. Any decision touching a live patent dispute should be verified independently and reviewed with qualified patent counsel.